RPRX
Price
$31.73
Change
+$0.46 (+1.47%)
Updated
Apr 3, 02:58 PM (EDT)
Capitalization
13.55B
34 days until earnings call
SLGL
Price
$0.46
Change
-$0.02 (-4.17%)
Updated
Apr 3, 02:18 PM (EDT)
Capitalization
13.48M
36 days until earnings call
Ad is loading...

RPRX vs SLGL

Header iconRPRX vs SLGL Comparison
Open Charts RPRX vs SLGLBanner chart's image
Royalty Pharma
Price$31.73
Change+$0.46 (+1.47%)
Volume$1.56K
Capitalization13.55B
Sol-Gel Technologies
Price$0.46
Change-$0.02 (-4.17%)
Volume$500
Capitalization13.48M
RPRX vs SLGL Comparison Chart
Loading...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RPRX vs. SLGL commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPRX is a Hold and SLGL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (RPRX: $31.28 vs. SLGL: $0.48)
Brand notoriety: RPRX and SLGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RPRX: 95% vs. SLGL: 75%
Market capitalization -- RPRX: $13.55B vs. SLGL: $13.48M
RPRX [@Biotechnology] is valued at $13.55B. SLGL’s [@Biotechnology] market capitalization is $13.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RPRX’s FA Score shows that 3 FA rating(s) are green whileSLGL’s FA Score has 0 green FA rating(s).

  • RPRX’s FA Score: 3 green, 2 red.
  • SLGL’s FA Score: 0 green, 5 red.
According to our system of comparison, RPRX is a better buy in the long-term than SLGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RPRX’s TA Score shows that 4 TA indicator(s) are bullish while SLGL’s TA Score has 4 bullish TA indicator(s).

  • RPRX’s TA Score: 4 bullish, 6 bearish.
  • SLGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SLGL is a better buy in the short-term than RPRX.

Price Growth

RPRX (@Biotechnology) experienced а -0.89% price change this week, while SLGL (@Biotechnology) price change was -13.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.22%. For the same industry, the average monthly price growth was -10.33%, and the average quarterly price growth was -14.34%.

Reported Earning Dates

RPRX is expected to report earnings on May 07, 2025.

SLGL is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-8.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RPRX($13.6B) has a higher market cap than SLGL($13.5M). RPRX YTD gains are higher at: 23.433 vs. SLGL (-47.963). RPRX has higher annual earnings (EBITDA): 1.56B vs. SLGL (-11.32M). RPRX has more cash in the bank: 1.77B vs. SLGL (28.1M). SLGL has less debt than RPRX: SLGL (1.31M) vs RPRX (7.61B). RPRX has higher revenues than SLGL: RPRX (2.26B) vs SLGL (11.7M).
RPRXSLGLRPRX / SLGL
Capitalization13.6B13.5M100,741%
EBITDA1.56B-11.32M-13,743%
Gain YTD23.433-47.963-49%
P/E Ratio16.32N/A-
Revenue2.26B11.7M19,350%
Total Cash1.77B28.1M6,302%
Total Debt7.61B1.31M582,848%
FUNDAMENTALS RATINGS
RPRX vs SLGL: Fundamental Ratings
RPRX
SLGL
OUTLOOK RATING
1..100
1468
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
55
Fair valued
PROFIT vs RISK RATING
1..100
28100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
4692
P/E GROWTH RATING
1..100
1697
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for SLGL (55). This means that RPRX’s stock grew somewhat faster than SLGL’s over the last 12 months.

RPRX's Profit vs Risk Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for SLGL (100). This means that RPRX’s stock grew significantly faster than SLGL’s over the last 12 months.

RPRX's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as SLGL (95). This means that RPRX’s stock grew similarly to SLGL’s over the last 12 months.

RPRX's Price Growth Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for SLGL (92). This means that RPRX’s stock grew somewhat faster than SLGL’s over the last 12 months.

RPRX's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for SLGL (97). This means that RPRX’s stock grew significantly faster than SLGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RPRXSLGL
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 23 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
64%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CUSRX12.510.20
+1.62%
Cullen Small Cap Value Retail
OFALX17.69N/A
N/A
Olstein All Cap Value C
MVISX38.78N/A
N/A
Patient Opportunity IS
JHDAX18.14N/A
N/A
JPMorgan Hedged Equity 2 A
VVJEX11.18N/A
N/A
Voya VACS Series MCV Fund

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+0.35%
AXON - RPRX
48%
Loosely correlated
+3.18%
MDGL - RPRX
31%
Poorly correlated
+3.28%
ARRY - RPRX
30%
Poorly correlated
+1.65%
QURE - RPRX
29%
Poorly correlated
+7.16%
SLGL - RPRX
28%
Poorly correlated
-1.49%
More

SLGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLGL has been loosely correlated with TRAW. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SLGL jumps, then TRAW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLGL
1D Price
Change %
SLGL100%
-1.49%
TRAW - SLGL
53%
Loosely correlated
+8.41%
RAPT - SLGL
45%
Loosely correlated
-0.85%
AVXL - SLGL
29%
Poorly correlated
+6.73%
RPRX - SLGL
29%
Poorly correlated
+0.35%
EYPT - SLGL
28%
Poorly correlated
+6.34%
More